Patient clinical and hematologic characteristics
| . | PC-AL (n = 544) . | PC–non-AL (n = 519) . | P . |
|---|---|---|---|
| Clinical parameters | |||
| Median age (range), y | 62 (36-82) | 57 (25-91) | .003 |
| Sex, n (%) | .01 | ||
| Male | 343 (63.0) | 287 (55.3) | |
| Female | 201 (37.0) | 232 (44.7) | |
| Karnofsky index, median (range) | 80 (30-100) | ||
| Hematologic parameters | |||
| Stage of plasma cell dyscrasia, n (%) | <.001 | ||
| MGUS | 164 (30.1) | 62 (11.9) | |
| SMM | 345 (63.4) | 156 (30.1) | |
| MM | 35 (6.4) | 301 (58.0) | |
| Bone marrow plasmocytosis, median (range), % | 12 (1-99) | 30 (1-100) | <.001 |
| Median bone marrow plasmocytosis according to stage of plasma cell dyscrasia, % | |||
| MGUS | 5.9 | 6.1 | |
| SMM | 18.7 | 23.3 | |
| MM | 46.8 | 55.8 | |
| Monoclonal protein, n (%) | <.001 | ||
| IgG | 157 (28.9) | 328 (63.2)* | |
| IgA | 49 (9.0) | 116 (22.4)* | |
| IgD | 6 (1.1) | 3 (0.6) | |
| Light chain only | 332 (61.0) | 66 (12.7) | |
| Light chain restriction, n (%) | <.001 | ||
| κ | 124 (22.8) | 322 (62.3)* | |
| λ | 420 (77.2) | 193 (37.3)* | |
| dLFC, median (range), mg/L | 306.2 (−17.7 to 19 251.5) | ||
| ≥180, n/N (%) | 340/533 (63.8) | ||
| Organ involvement | |||
| No. of involved organs, median (range) | 3 (1-7) | ||
| Heart involvement, n/N (%) | 429/544 (78.9) | ||
| Mayo stage 2004, N (%)† | |||
| I | 73 (13.8) | ||
| II | 196 (37.2) | ||
| III | 258 (49.0) | ||
| NT-pro-BNP, median (range), ng/L | 4134 (22-565 442) | ||
| Soft tissue involvement, n/N (%) | 249/543 (45.9) | ||
| Renal involvement, n/N (%) | 233/543 (57.1) | ||
| Renal stage, N (%) | |||
| 1 | 271 (52.0) | ||
| 2 | 192 (36.9) | ||
| 3 | 58 (11.1) | ||
| GI tract involvement, n/N (%) | 192/544 (35.3) | ||
| Liver involvement, n/N (%) | 104/543 (19.2) | ||
| Peripheral neuropathy, n/N (%) | 88/543 (16.2) |
| . | PC-AL (n = 544) . | PC–non-AL (n = 519) . | P . |
|---|---|---|---|
| Clinical parameters | |||
| Median age (range), y | 62 (36-82) | 57 (25-91) | .003 |
| Sex, n (%) | .01 | ||
| Male | 343 (63.0) | 287 (55.3) | |
| Female | 201 (37.0) | 232 (44.7) | |
| Karnofsky index, median (range) | 80 (30-100) | ||
| Hematologic parameters | |||
| Stage of plasma cell dyscrasia, n (%) | <.001 | ||
| MGUS | 164 (30.1) | 62 (11.9) | |
| SMM | 345 (63.4) | 156 (30.1) | |
| MM | 35 (6.4) | 301 (58.0) | |
| Bone marrow plasmocytosis, median (range), % | 12 (1-99) | 30 (1-100) | <.001 |
| Median bone marrow plasmocytosis according to stage of plasma cell dyscrasia, % | |||
| MGUS | 5.9 | 6.1 | |
| SMM | 18.7 | 23.3 | |
| MM | 46.8 | 55.8 | |
| Monoclonal protein, n (%) | <.001 | ||
| IgG | 157 (28.9) | 328 (63.2)* | |
| IgA | 49 (9.0) | 116 (22.4)* | |
| IgD | 6 (1.1) | 3 (0.6) | |
| Light chain only | 332 (61.0) | 66 (12.7) | |
| Light chain restriction, n (%) | <.001 | ||
| κ | 124 (22.8) | 322 (62.3)* | |
| λ | 420 (77.2) | 193 (37.3)* | |
| dLFC, median (range), mg/L | 306.2 (−17.7 to 19 251.5) | ||
| ≥180, n/N (%) | 340/533 (63.8) | ||
| Organ involvement | |||
| No. of involved organs, median (range) | 3 (1-7) | ||
| Heart involvement, n/N (%) | 429/544 (78.9) | ||
| Mayo stage 2004, N (%)† | |||
| I | 73 (13.8) | ||
| II | 196 (37.2) | ||
| III | 258 (49.0) | ||
| NT-pro-BNP, median (range), ng/L | 4134 (22-565 442) | ||
| Soft tissue involvement, n/N (%) | 249/543 (45.9) | ||
| Renal involvement, n/N (%) | 233/543 (57.1) | ||
| Renal stage, N (%) | |||
| 1 | 271 (52.0) | ||
| 2 | 192 (36.9) | ||
| 3 | 58 (11.1) | ||
| GI tract involvement, n/N (%) | 192/544 (35.3) | ||
| Liver involvement, n/N (%) | 104/543 (19.2) | ||
| Peripheral neuropathy, n/N (%) | 88/543 (16.2) |